Breaking news

Nvidia Faces Historic Market Loss As DeepSeek Dents Confidence In AI’s Future

Nvidia experienced the largest single-day market cap drop in history on Monday, as its stock tumbled by 17%, shedding nearly $600 billion in value. This staggering loss is directly linked to a new development in the AI space—DeepSeek, a Chinese AI firm that unveiled its version of ChatGPT, raising concerns over the cost-efficiency and competitive positioning of U.S. AI companies.

Key Details

Nvidia’s shares experienced a severe decline, marking its worst daily percentage drop since March 2020, during the initial shock of the COVID-19 pandemic. On Monday, Nvidia lost a record-breaking $589 billion in market capitalization, more than doubling the previous one-day loss of $279 billion in September 2024. To put it into perspective, this is significantly more than Meta’s $251 billion market cap loss in February 2022.

As a result, Nvidia’s market valuation dropped from $3.5 trillion to $2.9 trillion, slipping behind Apple and Microsoft as the world’s most valuable company. Nvidia’s dramatic fall led a broader retreat in U.S. stocks, with the S&P 500 losing 1.5% and the Nasdaq dropping 3.1%. Other major players in the AI industry, such as chipmakers Arm and Broadcom, alongside Oracle, saw their stocks plummet by at least 10%.

The DeepSeek Effect

The cause of Nvidia’s catastrophic loss lies in DeepSeek’s release of its large-language model, which has cast doubt on the continued dominance of U.S. companies in generative AI. Initially, this might not seem like a negative development for Nvidia, as DeepSeek’s model was also powered by Nvidia’s powerful graphics processing units (GPUs), just like many other AI technologies. However, DeepSeek revealed that it spent just $5.6 million on Nvidia’s technology to develop its model. While experts believe this figure is likely a significant underestimation, it still calls into question the very foundation of Nvidia’s meteoric stock rise.

In recent years, Nvidia’s profits have skyrocketed, with projections indicating net profits could soar from $4.8 billion in 2022 to $66.7 billion in 2024, largely due to the soaring demand for its high-priced GPUs, which can cost up to $25,000 each. U.S. tech giants such as Meta, Tesla, and OpenAI have been among Nvidia’s biggest customers. However, if companies like these can replicate DeepSeek’s cost-efficient approach by using cheaper GPUs, Nvidia could face significant challenges in maintaining its market dominance.

As Ed Yardeni of Yardeni Research pointed out, this shift could be an unwelcome development for Nvidia.

Surprising Statistic

Nvidia’s near-$600 billion market cap loss on Monday exceeds the market values of all but 13 American companies, surpassing industry giants like UnitedHealth, Exxon Mobil, and Costco.

CEO’s Losses

Nvidia CEO Jensen Huang saw his wealth take a massive hit, losing $21 billion in a single day. His net worth dropped from $124.4 billion to $103.1 billion, according to Forbes estimates. Huang remains the largest individual shareholder in Nvidia, owning a 3% stake in the company.

Nvidia’s colossal market cap loss highlights the growing uncertainties in the AI sector, as DeepSeek’s cost-effective alternative to American AI models threatens to disrupt the industry’s balance. With AI becoming an increasingly competitive and global field, Nvidia’s future may hinge on how it adapts to these emerging challenges.

Medochemie And Theramir Announce Strategic Investment Agreement To Advance Biotech Manufacturing In Cyprus

Pharmaceutical manufacturer Medochemie and biotechnology company Theramir, both Cyprus-based, have announced a strategic investment agreement and collaboration aimed at developing next-generation biological therapies and expanding manufacturing capabilities in Cyprus.

The agreement, announced on 2 September 2026, brings together Medochemie’s experience in pharmaceutical manufacturing and Theramir’s biotechnology research. The companies said the collaboration would support advanced pharmaceutical manufacturing in Cyprus and south-eastern Europe.

What The Partnership Covers

Medochemie’s contribution will include its expertise in manufacturing sterile therapeutic products and its access to international markets.

Theramir develops technologies based on extracellular vesicles and microRNAs. Its work includes using stem-cell-derived extracellular vesicles to deliver microRNAs, small, non-coding RNA molecules that regulate genes and biological pathways associated with cancer growth and metastasis.

Under the agreement, the companies will jointly support the development of “Good Manufacturing Practice” capabilities for next-generation biological therapies. The partnership is also intended to help move these therapies towards clinical development.

A Wider Role For Cyprus

The collaboration will also support Theramir’s wider research programme. According to the companies, it is intended to strengthen Cyprus’s biotechnology infrastructure and expand local capacity in next-generation biomanufacturing.

They present the agreement as a step towards giving Cyprus a larger role in biotechnology and advanced pharmaceutical manufacturing for south-eastern Europe and international markets.

eCredo
Uol
Aretilaw firm
The Future Forbes Realty Global Properties

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter